In the September issue of Pharmaceutical Executive, Lev Gerlovin addresses four main questions that US drugmakers must answer to cope with the evolving payer landscape given rising drug prices. To read the article, click the link below.
Gene therapy competitive dynamics: Winner takes all?
This article was originally published in Cell & Gene. It has also been published in Cell & Gene‘s sister publication, OutSourced Pharama. With many gene...